Another major milestone has reshaped the T‑cell engager landscape. Vir Biotechnology and Astellas Pharma have entered a new global strategic partnership valued at $1.71 billion to advance Vir’s PSMA‑targeting PROXTEN dual‑masked T‑cell engager program. The deal represents one of the most significant investments in the TCE space this year, reinforcing industry confidence in next‑generation, tissue‑selective immune‑engaging modalities.
This collaboration is expected to accelerate the development of PROXTEN masked TCEs, designed to enable protease‑specific activation within the tumor microenvironment, offering a promising path to improved safety profiles and reduced on‑target, off‑tumor toxicity.
Hear Directly From Vir at the 8th T Cell Engager Therapeutics Summit
Building on this momentum, Vir Biotechnology will be joining the 8th T Cell Engager Therapeutics Summit to present their latest insights. Their upcoming session, “PROXTEN Masked T Cell Engagers: A Novel Therapeutic Approach Enabling Protease‑Specific Activation of TCEs Within the Tumor Microenvironment to Protect Healthy Tissues & Reduce Toxicity,” will provide an in‑depth look at the science behind this pioneering approach.
As strategic collaborations and investment continue to accelerate across the TCE field, this year’s summit offers a timely opportunity to hear firsthand how leading developers are driving the next wave of precision‑engineered T‑cell engager therapies.